A multicentre randomised controlled trial to evaluate the efficacy, morbidity and functional outcome of endoscopic transanal proctectomy versus laparoscopic proctectomy for low-lying rectal cancer (ETAP-GRECCAR 11 TRIAL): rationale and design

Bernard Lelong, Cécile de Chaisemartin, Helene Meillat, Sandra Cournier, Jean Marie Boher, Dominique Genre, Mehdi Karoui, Jean Jacques Tuech, Jean Robert Delpero, French Research Group of Rectal Cancer Surgery (GRECCAR), Bernard Lelong, Cécile de Chaisemartin, Helene Meillat, Sandra Cournier, Jean Marie Boher, Dominique Genre, Mehdi Karoui, Jean Jacques Tuech, Jean Robert Delpero, French Research Group of Rectal Cancer Surgery (GRECCAR)

Abstract

Background: Total mesorectal excision is the standard surgical treatment for mid- and low-rectal cancer. Laparoscopy represents a clear leap forward in the management of rectal cancer patients, offering significant improvements in post-operative measures such as pain, first bowel movement, and hospital length of stay. However, there are still some limits to its applications, especially in difficult cases. Such cases may entail either conversion to an open procedure or positive resection margins. Transanal endoscopic proctectomy (ETAP) was recently described and could address the difficulties of approaching the lower third of the rectum. Early series and case-control studies have shown favourable short-term results, such as a low conversion rate, reduced hospital length of stay and oncological outcomes comparable to laparoscopic surgery. The aim of the proposed study is to compare the rate of positive resection margins (R1 resection) with ETAP versus laparoscopic proctectomy (LAP), with patients randomly assigned to each arm.

Methods/design: The proposed study is a multicentre randomised trial using two parallel groups to compare ETAP and LAP. Patients with T3 lower-third rectal adenocarcinomas for whom conservative surgery with manual coloanal anastomosis is planned will be recruited. Randomisation will be performed immediately prior to surgery after ensuring that the patient meets the inclusion criteria and completing the baseline functional and quality of life tests. The study is designed as a non-inferiority trial with a main criterion of R0/R1 resection. Secondary endpoints will include the conversion rate, the minimal invasiveness of the abdominal approach, postoperative morbidity, the length of hospital stay, mesorectal macroscopic assessment, functional urologic and sexual results, faecal continence, global quality of life, stoma-free survival, and disease-free survival at 3 years. The inclusion period will be 3 years, and every patient will be followed for 3 years. The number of patients needed is 226.

Discussion: There is a strong need for optimal evaluation of the ETAP because of substancial changes in the operative technique. Assessment of oncological safety and septic risk, as well as digestive and urological functional results, is particularily mandatory. Moreover, benefits of the ETAP technique could be demonstrated in post-operative outcome.

Trial registration: ClinicalTrial.gov: NCT02584985 . Date and version identifier: Version n°2 - 2015 July 6.

Keywords: Minimally invasive; Rectal cancer; Transanal approach.

Figures

Fig. 1
Fig. 1
Study scheme of ETAP-GRECCAR 11 trial, inclusion and exclusion criteria, intervention, and end points (DFS, Disease-Free Survival)

References

    1. Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet. 1986;1:1479–1482. doi: 10.1016/S0140-6736(86)91510-2.
    1. Martling A, Cedermark B, Johansson H, Rutqvist LE, Holm T. The surgeon as a prognostic factor after the introduction of total mesorectal excision in the treatment of rectal cancer. Br J Surg. 2002;89:1008–1013. doi: 10.1046/j.1365-2168.2002.02151.x.
    1. Nagtegaal ID, Marijnen CA, Kranenbarg EK, Van de Velde CJ, van Krieken JH, Pathology Review Committee. Cooperative Clinical Investigators Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: not one millimeter but two millimeters is the limit. Am J Surg Pathol. 2002;26:350–357. doi: 10.1097/00000478-200203000-00009.
    1. Adam IJ, Mohamdee MO, Martin IG, Scott N, Finan PJ, Johnston D, et al. Role of circumferential margin involvement in the local recurrence of rectal cancer. Lancet. 1994;344:707–711. doi: 10.1016/S0140-6736(94)92206-3.
    1. Martling A, Holm T, Rutqvist LE, Johansson H, Moran BJ, Heald RJ, et al. Impact of a surgical training programme on rectal cancer outcomes in Stockholm. Br J Surg. 2005;92:225–229. doi: 10.1002/bjs.4834.
    1. Jayne DG, Guillou PJ, Thorpe H, Quirke P, Copeland J, Smith AM, et al. Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial Group. J Clin Oncol. 2007;25:3061–3068. doi: 10.1200/JCO.2006.09.7758.
    1. Van der Pas MH, Haglind E, Cuesta MA, Fürst A, Lacy AM, Hop WC, et al. Laparoscopic versus open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trial. Lancet Oncol. 2013;14:210–218. doi: 10.1016/S1470-2045(13)70016-0.
    1. Kang SB, Park JW, Jeong SY, Nam BH, Choi HS, Kim DW, et al. Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): short-term outcomes of an open-label randomised controlled trial. Lancet Oncol. 2010;11:637–645. doi: 10.1016/S1470-2045(10)70131-5.
    1. Bonjer HJ, Deijen CL, Abis GA, Cuesta MA, van der Pas MH, de Lange-de Klerk ES, et al. A randomized trial of laparoscopic versus open surgery for rectal cancer. N Engl J Med. 2015;372:1324–1332. doi: 10.1056/NEJMoa1414882.
    1. Guillou PJ, Quirke P, Thorpe H, Walker J, Jayne DG, Smith AM, et al. Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial. Lancet. 2005;365:1718–1726. doi: 10.1016/S0140-6736(05)66545-2.
    1. Miyajima N, Fukunaga M, Hasegawa H, Tanaka J, Okuda J, Watanabe M, et al. Results of a multicenter study of 1,057 cases of rectal cancer treated by laparoscopic surgery. Surg Endosc. 2009;23:113–118. doi: 10.1007/s00464-008-0078-7.
    1. Thorpe H, Jayne DG, Guillou PJ, Quirke P, Copeland J, Brown JM, et al. Patient factors influencing conversion from laparoscopically assisted to open surgery for colorectal cancer. Br J Surg. 2008;95:199–205. doi: 10.1002/bjs.5907.
    1. Fleshman J, Branda M, Sargent DJ, Boller AM, George V, Abbas M, et al. Effect of laparoscopic-assisted resection vs open resection of stage II or III rectal cancer on pathologic outcomes: the ACOSOG Z6051 randomized clinical trial. JAMA. 2015;314:1346–1355. doi: 10.1001/jama.2015.10529.
    1. Stevenson ARL, Solomon MJ, Lumley JW, Hewett P, Clouston AD, Gebski VJ, et al. Effect of laparoscopic-assisted resection vs open resection on pathologic outcome in rectal cancer, the ALaCaRT randomized clinical trial. JAMA. 2015;314:1356–1363. doi: 10.1001/jama.2015.12009.
    1. Broholm M, Pommergaard HC, Gögenür I. Possible benefits of robot-assisted rectal cancer surgery regarding urological and sexual dysfunction: a systematic review and meta-analysis. Colorectal Dis. 2015;17:375–381. doi: 10.1111/codi.12872.
    1. Heald RJ. A new solution to some old problems: transanal TME. Tech Coloproctol. 2013;17:257–258. doi: 10.1007/s10151-013-0984-0.
    1. Aigner F, Hörmann R, Fritsch H, Pratschke J, D’Hoore A, Brenner E, et al. Anatomical considerations for transanal minimal-invasive surgery: the caudal to cephalic approach. Colorectal Dis. 2015;17:O47–O53. doi: 10.1111/codi.12846.
    1. Sylla P, Rattner DW, Delgado S, Lacy AM. NOTES transanal rectal cancer resection using transanal endoscopic microsurgery and laparoscopic assistance. Surg Endosc. 2010;24:1205–1210. doi: 10.1007/s00464-010-0965-6.
    1. Tuech JJ, Bridoux V, Kianifard B, Schwarz L, Tsilividis B, Huet E, et al. Natural orifice total mesorectal excision using transanal port and laparoscopic assistance. Eur J Surg Oncol. 2011;37:334–335. doi: 10.1016/j.ejso.2010.12.016.
    1. Dumont F, Goéré D, Honoré C, Elias D. Transanal endoscopic total mesorectal excision combined with single-port laparoscopy. Dis Colon Rectum. 2012;55:996–1001. doi: 10.1097/DCR.0b013e318260d3a0.
    1. Rouanet P, Mourregot A, Azar CC, Carrere S, Gutowski M, Quenet F, et al. Transanal endoscopic proctectomy: an innovative procedure for difficult resection of rectal tumors in Men with narrow pelvis. Dis Colon Rectum. 2013;56:408–415. doi: 10.1097/DCR.0b013e3182756fa0.
    1. Lacy AM, Tasende MM, Delgado S, Fernandez-Hevia M, Jimenez M, De Lacy B, et al. Transanal Total Mesorectal excision for rectal cancer: outcomes after 140 patients. J Am Coll Surg. 2015;221:415–423. doi: 10.1016/j.jamcollsurg.2015.03.046.
    1. Veltcamp Helbach M, Deijen CL, Velthuis S, Bonjer HJ, Tuynman JB, Sietses C. Transanal total mesorectal excision for rectal carcinoma: short-term outcomes and experience after 80 cases. Surg Endosc. 2016;30:464–470. doi: 10.1007/s00464-015-4221-y.
    1. Tuech JJ, Karoui M, Lelong B, De Chaisemartin C, Bridoux V, Manceau G, et al. A step toward NOTES total mesorectal excision for rectal cancer: endoscopic transanal proctectomy. Ann Surg. 2015;261:228–233. doi: 10.1097/SLA.0000000000000994.
    1. Burke JP, Martin-Perez B, Khan A, Nassif G, de Beche-Adams T, Larach SW, et al. Transanal Total Mesorectal excision for rectal cancer: early outcomes in 50 consecutive patients. Colorectal Dis. 2016;18:570–577. doi: 10.1111/codi.13263.
    1. Bertrand MM, Colombo PE, Alsaid B, Prudhomme M, Rouanet P. Transanal endoscopic proctectomy and nerve injury risk: bottom to top surgical anatomy, key points. Dis Colon Rectum. 2014;57:1145–1148. doi: 10.1097/DCR.0000000000000187.
    1. Velthuis S, Nieuwenhuis DH, Ruijter TE, Cuesta MA, Bonjer HJ, Sietses C. Transanal versus traditional laparoscopic total mesorectal excision for rectal carcinoma. Surg Endosc. 2014;28:3494–3499. doi: 10.1007/s00464-014-3636-1.
    1. Fernández-Hevia M, Delgado S, Castells A, Tasende M, Momblan D, Díaz Del Gobbo G, et al. Transanal total mesorectal excision in rectal cancer: short-term outcomes in comparison with laparoscopic surgery. Ann Surg. 2015;26:221–227. doi: 10.1097/SLA.0000000000000865.
    1. Chen CC, Lai YL, Jiang JK, Chu CH, Huang IP, Chen WS, et al. Transanal total mesorectal excision versus laparoscopic surgery for rectal cancer receiving neoadjuvant chemoradiation: a matched case-control study. Ann Surg Oncol. 2016;23:1169–1176. doi: 10.1245/s10434-015-4997-y.
    1. Lelong B, Meillat H, Zemmour C, Poizat F, Ewald J, Mege D, et al. Short- and Mid-Term Outcomes after Endoscopic Transanal or Laparoscopic Transabdominal Total Mesorectal Excision for Low Rectal Cancer: a Single Institutional Case-control Study. J Am Coll Surg. 2016. doi:10.1016/j.jamcollsurg.2016.12.019.
    1. Kirwan WO, Turnbull RB, Jr, Fazio VW, Weakley FL. Pullthrough operation with delayed anastomosis for rectal cancer. Br J Surg. 1978;65(10):695–698. doi: 10.1002/bjs.1800651008.
    1. Bege T, Lelong B, Esterni B, Turrini O, Guiramand J, Francon D, et al. The learning curve for the laparoscopic approach to conservative mesorectal excision for rectal cancer: lessons drawn from a single institution’s experience. Ann Surg. 2010;251:249–253. doi: 10.1097/SLA.0b013e3181b7fdb0.
    1. Rullier E, Denost Q, Vendrely V, Rullier A, Laurent C. Low rectal cancer: classification and standardization of surgery. Dis Colon Rectum. 2013;56:560–567. doi: 10.1097/DCR.0b013e31827c4a8c.
    1. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–213. doi: 10.1097/.
    1. Nagtegaal ID, van de Velde CJ, van der Worp E, Kapiteijn E, Quirke P, van Krieken JH, et al. Macroscopic evaluation of rectal cancer resection specimen: clinical significance of the pathologist in quality control. J Clin Oncol. 2002;20:1729–1734. doi: 10.1200/JCO.2002.07.010.
    1. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–1474. doi: 10.1245/s10434-010-0985-4.
    1. Haab F, Richard F, Amarenco G, Coloby P, Arnould B, Benmedjahed K, et al. Comprehensive evaluation of bladder and urethral dysfunction symptoms: development and psychometric validation of the urinary symptom profile (USP) questionnaire. Urol. 2008;71:646–656. doi: 10.1016/j.urology.2007.11.100.
    1. Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, et al. The female sexual function index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000;26:191–208. doi: 10.1080/009262300278597.
    1. Rhoden EL, Telöken C, Sogari PR, Vargas Souto CA. The use of the simplified International index of erectile function (IIEF-5) as a diagnostic tool to study the prevalence of erectile dysfunction. Int J Impot Res. 2002;14:245–250. doi: 10.1038/sj.ijir.3900859.
    1. Jorge JM, Wexner SD. Etiology and management of fecal incontinence. Dis Colon Rectum. 1993;36:77–97. doi: 10.1007/BF02050307.
    1. Kaasa S, Bjordal K, Aaronson N, Moum T, Wist E, Hagen S, et al. The EORTC core quality of life questionnaire (QLQ-C30): validity and reliability when analysed with patients treated with palliative radiotherapy. Eur J Cancer. 1995;31A:2260–2263. doi: 10.1016/0959-8049(95)00296-0.
    1. Velthuis S, Veltcamp Helbach M, Tuynman JB, Le TN, Bonjer HJ, Sietses C. Intra-abdominal bacterial contamination in TAMIS total mesorectal excision for rectal carcinoma: a prospective study. Surg Endosc. 2015;29:3319–3323. doi: 10.1007/s00464-015-4089-x.
    1. Joo JS, Latulippe JF, Alabaz O, Weiss EG, Nogueras JJ, Wexner SD. Long-term functional evaluation of straight coloanal anastomosis and colonic J-pouch: is the functional superiority of colonic J-pouch sustained? Dis Colon Rectum. 1998;41:740–746. doi: 10.1007/BF02236262.
    1. Herman RM, Richter P, Walega P, Popiela T. Anorectal sphincter function and rectal barostat study in patients following transanal endoscopic microsurgery. Int J Colorectal Dis. 2001;16:370–376. doi: 10.1007/s003840100325.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever